Our Mission

Deliver medicines that transform the lives of patients with neurodegenerative diseases

Our Focus

Founded in 2019, Vanqua Bio is a biopharmaceutical company focused on discovering and developing next-generation medicines for neurodegenerative diseases. Our novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to advance needed therapies. Our lead program targets glucocerebrosidase (GCase) as a potential treatment for Parkinson’s disease (PD) and Dementia with Lewy Bodies (DLB). Additional programs address overactivation of the innate immune system in central and peripheral disorders, including Alzheimer’s disease.


I am humbled and inspired every day by the opportunity to make a profound difference in the lives of patients. It is my privilege to lead Vanqua Bio’s team of outstanding scientists on our journey to vanquish these devastating conditions.

Jim Sullivan Ph.D., Vanqua Bio CEO

Our Partners

Vanqua Bio’s investors and partners are committed leaders in Parkinson’s disease, neuroscience research, and lifescience investments.